source
- Eli Lilly's $3.8 B acquisition of AtaiBeckley signals growing confidence in psychedelics for depressionPsychedelics are being touted as a potential solution for patients who still struggle to find lasting relief from existing FDA‑approved psychiatric medicines. The article notes that many individual…
- Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecastsDenali Therapeutics reported that its newly launched Hunter syndrome therapy Avlayah earned $3.6 million in revenue during the first quarter after its April market entry. Analysts had projected ro…